Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PALI
SELLREMOVEPalisade Bio, Inc. · Healthcare · United States · $358M · Avg Vol: $5M/d
Micro-cap biotech with high cash burn and binary clinical risks, completely outside our quality and margin of safety parameters.
COMPANY DESCRIPTION
Palisade Bio, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory and fibrotic diseases, with a lead candidate aimed at protecting the gastrointestinal tract. The company's competitive standing relies on the successful progression of its proprietary drug candidates through rigorous clinical trials and subsequent regulatory approval. As a development-stage firm, its valuation is heavily tied to its pipeline's potential.
FINANCIAL SUMMARY
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 250,000 | 0 | 0 | — |
| EPS | — | -247.95 | -27.01 | -10.19 | -0.30 | — |
| Shares | — | 396,287 | 818,059 | 3M | 160M | +40184.9% |
| Debt | — | 404,000 | 369,000 | 169,000 | 71,000 | -44.0% |
| Equity | — | 12M | 11M | 7M | 129M | 118.1% |
| Op CF | — | -13M | -11M | -12M | -11M | — |
| Inv CF | -54,000 | -10,000 | -4,000 | 0 | — | — |
| Fin CF | — | 15M | 11M | 10M | 134M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PALI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PALI | Palisade Bio, Inc.(you) | $358M | 34 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $313M | 35 | SELL |
| NAUT | Nautilus Biotechnology, Inc. | $330M | 32 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $390M | 36 | HOLD |
| FATE | Fate Therapeutics, Inc. | $307M | 35 | HOLD |
| ARTV | Artiva Biotherapeutics, Inc. | $370M | 39 | HOLD |
| PRTC.L | PureTech Health plc | $455M | 35 | SELL |
| IRD | Opus Genetics, Inc. | $342M | 39 | HOLD |
| SABS | SAB Biotherapeutics, Inc. | $273M | 34 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $385M | 30 | SELL |
Peer medians: ROE -21.9% · P/E 25.3x · Gross margin 44.3%